# Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province

> **NCT05470855** · PHASE4 · UNKNOWN · sponsor: **Sinovac (Dalian) Vaccine Technology Co., Ltd.** · enrollment: 45400 (estimated)

## Conditions studied

- Varicella

## Interventions

- **BIOLOGICAL:** Live attenuated varicella vaccine

## Key facts

- **NCT ID:** NCT05470855
- **Lead sponsor:** Sinovac (Dalian) Vaccine Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-06
- **Primary completion:** 2022-11-30
- **Final completion:** 2023-02-10
- **Target enrollment:** 45400 (ESTIMATED)
- **Last updated:** 2023-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05470855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05470855, "Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05470855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*